CRB-701 Shows Robust Phase 1/2 Oncology Data; FDA Aligns on Registrational Study Designs
CRBP sits 53% above its 52-week low of $6.72 on elevated volume (2.1× avg).
Summary
Corbus Pharmaceuticals announced strong Phase 1/2 clinical data for its lead oncology drug, CRB-701, in oropharyngeal and cervical cancers, along with FDA alignment on registrational study designs.
Key Events · Product Development and Regulatory · CRBP
-
Robust Phase 1/2 Data for CRB-701
Updated clinical data from the Phase 1/2 study of CRB-701 showed a 42.9% confirmed objective response rate (cORR) in 2L oropharyngeal squamous cell carcinoma (OPSCC) and 34.4% cORR in 2L cervical cancer at the 3.6 mg/kg dose, with a manageable safety profile.
-
FDA Alignment on Registrational Studies
The company achieved broad alignment with the FDA on the design of registrational studies for CRB-701 in both 2L OPSCC and 2L cervical cancer, with the OPSCC study ("TEMPO-1") expected to begin in summer 2026.
-
Upcoming ASCO Presentation
The detailed clinical findings will be presented at the 2026 American Society for Clinical Oncology (ASCO) Annual Meeting from May 29 – June 2, 2026, with an oral presentation on May 29 and a poster on May 30.
Analysis · CRBP · Life Sciences
This filing provides highly positive clinical data for Corbus's lead oncology asset, CRB-701, demonstrating robust efficacy and a favorable safety profile in two difficult-to-treat cancers. The confirmed alignment with the FDA on registrational study designs for both oropharyngeal squamous cell carcinoma and cervical cancer significantly de-risks the development pathway, providing a clear route to potential market approval. This progress is critical for a clinical-stage biotech, potentially enhancing its valuation and future financing prospects, especially given recent reports of increased cash burn.
How filings like this one have moved
In the 30 days to Aug 24, 2026, 44% of the 972 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRBP was trading at $10.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $210.3M. The 52-week trading range was $6.72 to $20.56. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.